The estimated Net Worth of Paula Hammond is at least $403 ezer dollars as of 12 August 2024. Paula Hammond owns over 10,500 units of Alector stock worth over $349,814 and over the last 5 years he sold ALEC stock worth over $53,130. In addition, he makes $0 as Independent Director at Alector.
Paula has made over 1 trades of the Alector stock since 2024, according to the Form 4 filled with the SEC. Most recently he sold 10,500 units of ALEC stock worth $53,130 on 12 August 2024.
The largest trade he's ever made was selling 10,500 units of Alector stock on 12 August 2024 worth over $53,130. On average, Paula trades about 1,750 units every 0 days since 2020. As of 12 August 2024 he still owns at least 60,209 units of Alector stock.
You can see the complete history of Paula Hammond stock trades at the bottom of the page.
Dr. Paula Hammond Ph.D. serves as Independent Director of the Company. Hammond is one of only 25 distinguished scientists elected to all three national academies, the National Academy of Sciences, the National Academy of Engineering and the National Academy of Medicine. Dr. Hammond is also a member of the American Academy of Arts and Sciences, has published over 300 papers and holds more than 20 patents based on her research at MIT. Dr. Hammond holds a Ph.D. and an S.B. in chemical engineering from MIT, and an M.S. in chemical engineering from the Georgia Institute of Technology. Her laboratory at MIT designs polymers and nanoparticles for targeted drug delivery to address cancer, wound healing and regenerative medicine.
Paula Hammond is 56, he's been the Independent Director of Alector since 2020. There are 8 older and 9 younger executives at Alector. The oldest executive at Alector, Inc. is Louis Lavigne, 72, who is the Lead Independent Director.
Paula's mailing address filed with the SEC is C/O ALECTOR, INC., 131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 5 years, insiders at Alector have traded over $148,873,269 worth of Alector stock and bought 20,000 units worth $500,000 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Advisors Llc Orbi Med Capit... és Terrance Mcguire. On average, Alector executives and independent directors trade stock every 17 days with the average trade being worth of $438,922. The most recent stock trade was executed by Marc Grasso on 3 September 2024, trading 7,297 units of ALEC stock currently worth $35,609.
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase Ib clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease; and 8 candidates in immuno-neurology/immuno-oncology field comprise ADP012, ADP016, ADP017, ADP023, ADP026, ADP122, ADP009, and ADP022. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Alector executives and other stock owners filed with the SEC include: